Game change: A frontrunner in the cell therapy 2.0 field offers a first look at their lead therapy. And it’s a doozy
When a pair of CAR-T pioneers from Juno launched Sana Biotechnology back at the beginning of 2019, they had some grand and rather vaguely defined plans on building multiple platforms to engineer cells — part of the whole cell therapy 2.0 movement that’s attracted billions of dollars in financing.
But, like most private startups, CEO Steve Harr and the crew kept the program details quiet, part of the inevitable “stealthy” approach on timelines and treatments you run into with ambitious players.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.